Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Rice Hall James & Associates LLC boosted its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 273.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 271,897 shares of the company's stock after buying an additional 199,110 shares during the quarter. Rice Hall James & Associates LLC owned approximately 1.16% of UroGen Pharma worth $3,453,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock valued at $103,000 after buying an additional 3,856 shares during the period. ProShare Advisors LLC bought a new stake in shares of UroGen Pharma during the 2nd quarter valued at about $199,000. SG Americas Securities LLC acquired a new stake in UroGen Pharma during the third quarter worth approximately $179,000. Main Street Financial Solutions LLC bought a new stake in UroGen Pharma in the second quarter worth approximately $403,000. Finally, Tidal Investments LLC acquired a new position in UroGen Pharma in the first quarter valued at approximately $425,000. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Stock Down 0.5 %

Shares of URGN traded down $0.06 on Friday, reaching $12.20. The company's stock had a trading volume of 603,192 shares, compared to its average volume of 767,347. UroGen Pharma Ltd. has a twelve month low of $10.60 and a twelve month high of $20.70. The stock has a market capitalization of $286.09 million, a PE ratio of -3.72 and a beta of 1.12. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. The firm has a fifty day moving average of $12.95 and a 200-day moving average of $14.24.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The firm had revenue of $21.85 million during the quarter, compared to analysts' expectations of $23.69 million. Equities analysts predict that UroGen Pharma Ltd. will post -3.49 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on URGN. HC Wainwright reiterated a "buy" rating and issued a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a "strong-buy" rating in a report on Monday, October 14th. Guggenheim initiated coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a "buy" rating and a $40.00 target price for the company. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $48.38.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.